Skip to content
DataLookout
Menu

NCT07691762

A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Sep 2026 to Nov 2026
    • Primary and study completion pushed from Apr 2031 to Sep 2031
  2. Notable Start date: Jul 2026 to Sep 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Interventions modified
    • Study sites: 1 to 2
    • Secondary endpoints revised (9)
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression-free survival (PFS) assessed by investigator
Timeframe: Until progression, assessed up to approximately 2 years.

Secondary (9)

Progression-free survival (PFS) assessed by Blinded Independent Review Committee (BIRC)
Overall survival (OS)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of objective tumor response (DoR)
Show 4 moreShow less
Adverse events (AEs)
Serious adverse events (SAEs)
Pharmacokinetics parameters of SHR-8068 and Adebrelimab: serum concentration
Immunogenicity indicators of SHR-8068 and Adebrelimab: drug resistant antibody (ADA) and neutralizing antibody (NAb)

Arms and interventions

Treatment group AExperimental

SHR-8068 + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE)

Treatment group BActive comparator

SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo + Transarterial Chemoembolization (TACE)

Treatment group CExperimental

SHR-8068 Placebo + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE)

Drugs: SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab

Sites

2 sites in 1 country